Who are Reprieve Cardiovascular's investors?

Reprieve Cardiovascular's investors include Arboretum Ventures, Lightstone Ventures, Rex Health Ventures, Deerfield Management Company, Genesis Venture Capital, Sante Ventures.

How much funding has Reprieve Cardiovascular raised?

Reprieve Cardiovascular has disclosed $82.4M raised across 5 rounds.

Where is Reprieve Cardiovascular headquartered?

Reprieve Cardiovascular is headquartered in Milford, US.

Reprieve Cardiovascular

Milford, US · Founded 2020 · Delaware corporation · 6 known investors

Find your way into Reprieve Cardiovascular

Paths you didn't know you had: your email and LinkedIn already hold routes to the Reprieve Cardiovascular team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients. The technology gives physicians and care teams visibility and control over treatment to accelerate fluid removal while managing kidney injury risk, targeting hospital-based heart failure care in the U.S.

Digital Health Healthtech Medical Devices

Founders & leadership

Tony FieldsExecutive

Adam Bartnik Chief Financial OfficerAdam Bartnik is a finance executive with over 20 years of experience in the biopharmaceutical industry, including roles in corporate and R&D financial planning and analysis, financial reporting, and controls at companies managing billion-dollar budgets. He is Executive Officer at Reprieve Cardiovascular, which develops a decongestion management system for heart failure patients.

Mark PacynaChief Executive Officer

Jim DillonExecutive

Hanson S. Gifford IIINamed on SEC filing

Gregory W MannNamed on SEC filing

Board

James Eadie Board directorManaging Director at Sante Ventures

David NeustaedterBoard Member

Ethan BenovitzBoard Member

Jan Garfinkle Board Member, InvestorFounder and Managing Partner at Arboretum Ventures

Andrew ElBardissi Board directorPartner at Deerfield Management Company

Investors · 6

Arboretum Ventureslisted by Arboretum VenturesAnn Arbor · $5M – $15Mvia Jan Garfinkle · board

How we know: Arboretum Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Lightstone Ventureslisted by Lightstone VenturesPortola Valleyvia Hanson S. Gifford, III · board

How we know: Lightstone Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Rex Health Ventureslisted by Rex Health VenturesRaleigh · $250K – $500K

How we know: Rex Health Ventures's portfolio page · funding news · Not right? Tell us

Deerfield Management CompanyreportedNew Yorkvia Andrew ElBardissi · board

How we know: board seat on SEC Form D · funding news · Not right? Tell us

Genesis Venture CapitalreportedGrand Cayman

How we know: funding news · Not right? Tell us

Sante VenturesreportedAustin · $2M – $6M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$82.4M disclosed across 5 rounds · 2020–2025

▶$30.9MraisedJun 2025 · 12 investors · Other Health Care

Rule 506(b)